المؤلفون: Regeneron Pharmaceuticals

المصدر: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04456673Test

Other URLs: http://www.copdclinicalstudies.com/?utm_source=ctgovTest

المؤلفون: Regeneron Pharmaceuticals

المصدر: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03930732Test